Ethyl 2-(3,4-dimethoxybenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Ethyl 2-(3,4-dimethoxybenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxylate
• 英文别名: ethyl 2-[(3,4-dimethoxyphenyl)methyl]-5-methyl-4-oxo-3H-thieno[2,3-d]pyrimidine-6-carboxylate
• 化学式: C₁₉H₂₀N₂O₅S
• mdl: MFCD05262620
• 分子量: 388.4
• InChiKey: IOSIAHQUXVYMEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.315
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• THIENOPYRIMIDINE DERIVATIVES
  申请人：GOTANDA Kotaro

  公开号：US20130023546A1

  公开（公告）日：2013-01-24

  This invention provides thienopyrimidine derivatives of the formula, wherein R 1 stands for hydrogen atom, an alkyl group or the like; R 2 stands for a hydrogen atom, an alkyl or amino group or the like, R 3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y—X—; or R 2 and R 3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH 2 , CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocycylic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4, or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.

  本发明提供了式子中的噻吩嘧啶衍生物，其中R1代表氢原子，烷基或类似物；R2代表氢原子，烷基或氨基基团或类似物，R3代表烷基，烯基或烷基硫基团或类似物或Y—X—基团；或者R2和R3可以形成四亚甲基基团；X代表直接键或连接基团，例如CH2，CH（OH），S，O，NH；Y代表取代或未取代的芳香环烷基，芳香杂环基，环烷基或饱和杂环基团或类似物；Z代表S或O，n为0或1到4的整数，或其盐。这些化合物在PDE9上具有抑制作用，因此可用于预防或治疗过度活动的膀胱综合症，尿频，尿失禁，前列腺增生症相关的排尿困难，泌尿结石，阿尔茨海默病，慢性阻塞性肺疾病，心肌梗死，血栓形成，糖尿病等。
• Thienopyrimidine Derivatives
  申请人：Gotanda Kotaro

  公开号：US20090203703A1

  公开（公告）日：2009-08-13

  This invention provides thienopyrimidine derivatives of the formula, wherein R 1 stands for hydrogen atom, an alkyl group or the like; R 2 stands for a hydrogen atom, an alkyl or amino group or the like, R 3 stands for an alkyl, alkenyl or alkylthio group or the like or a group Y—X—; or R 2 and R 3 may together form tetramethylene group; X standing for a direct bond or linking group such as CH 2 , CH(OH), S, O, NH; Y standing for a substituted or unsubstituted aromatic carbocycylic, aromatic heterocylic, cycloalkyl or saturated heterocyclic group or the like; Z stands for S or O, and n is 0 or an integer of 1 to 4, or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.

  该发明提供了式子中的噻吩嘧啶衍生物，其中R1代表氢原子、烷基或类似基团；R2代表氢原子、烷基或氨基等基团，R3代表烷基、烯基或烷硫基等基团或Y—X—基团；或R2和R3可以共同形成四亚甲基基团；X代表直接键或连接基团，如CH2，CH（OH），S，O，NH；Y代表取代或未取代的芳香环烷基、芳香杂环基、环烷基或饱和杂环基等基团；Z代表S或O，n为0或1至4的整数，或其盐。这些衍生物对PDE9具有抑制作用，因此可用于预防或治疗过度活跃的膀胱综合症、尿频、尿失禁、前列腺增生引起的排尿困难、泌尿结石、阿尔茨海默病、慢性阻塞性肺疾病、心肌梗死、血栓形成、糖尿病等疾病。
• THIENOPYRIMIDINE DERIVATIVE
  申请人：ASKA Pharmaceutical Co., Ltd.

  公开号：EP1908765B1

  公开（公告）日：2014-10-22
• US8293754B2
  申请人：——

  公开号：US8293754B2

  公开（公告）日：2012-10-23
• US8377944B2
  申请人：——

  公开号：US8377944B2

  公开（公告）日：2013-02-19